Inscrição na biblioteca: Guest
Critical Reviews™ in Eukaryotic Gene Expression

Publicou 6 edições por ano

ISSN Imprimir: 1045-4403

ISSN On-line: 2162-6502

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 1.6 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 2.2 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.3 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00058 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.33 SJR: 0.345 SNIP: 0.46 CiteScore™:: 2.5 H-Index: 67

Indexed in

Cyclic Peptides for Protein−Protein Interaction Targets: Applications to Human Disease

Volume 26, Edição 3, 2016, pp. 199-221
DOI: 10.1615/CritRevEukaryotGeneExpr.2016016525
Get accessGet access

RESUMO

Protein−protein interactions (PPIs) represent a significant portion of functionally relevant biological interactions, and therefore potential therapeutic targets. Small molecules were traditionally used to target PPIs. However, many PPI surfaces lack binding pockets due to their large and flat structures. Antibodies can also be used to modulate PPIs, but they are expensive and not cell permeable. Linear peptides are less expensive to produce than antibodies and are generally more selective than small molecules, but they are limited by decreased stability and poor permeability. Modified peptides (peptidomimetics, e.g., cyclic peptides) can overcome these obstacles. Advantages of using cyclic peptidomimetics to modulate PPIs derive from their conformational constraint, which supports target specificity, cell permeability, and metabolic stability. Methods for rational design coupled with high-throughput techniques continue to support advances in the field. Further development of cyclic peptidomimetics to modulate PPIs will improve treatment of human diseases, such as cancer, infection, neurodegeneration, and autoimmunity. Here we describe several cyclic peptidomimetics that are currently used as drugs and many potential cyclic peptides PPI inhibitors in different stages of pre-clinical and clinical development. Further development of cyclic peptidomimetics to modulate PPIs will continue to improve treatment of human diseases, such as cancer, infection, neurodegeneration, and autoimmunity.

CITADO POR
  1. Schneider Jeffrey A., Craven Timothy W., Kasper Amanda C., Yun Chi, Haugbro Michael, Briggs Erica M., Svetlov Vladimir, Nudler Evgeny, Knaut Holger, Bonneau Richard, Garabedian Michael J., Kirshenbaum Kent, Logan Susan K., Design of Peptoid-peptide Macrocycles to Inhibit the β-catenin TCF Interaction in Prostate Cancer, Nature Communications, 9, 1, 2018. Crossref

  2. Morrison Michael J., Boriack-Sjodin P. Ann, Swinger Kerren K., Wigle Tim J., Sadalge Dipti, Kuntz Kevin W., Scott Margaret Porter, Janzen William P., Chesworth Richard, Duncan Kenneth W., Harvey Darren M., Lampe John W., Mitchell Lorna H., Copeland Robert A., Jeltsch Albert, Identification of a peptide inhibitor for the histone methyltransferase WHSC1, PLOS ONE, 13, 5, 2018. Crossref

  3. Geranurimi Azade, Cheng Colin W. H., Quiniou Christiane, Zhu Tang, Hou Xin, Rivera José Carlos, St-Cyr Daniel J., Beauregard Kim, Bernard-Gauthier Vadim, Chemtob Sylvain, Lubell William D., Probing Anti-inflammatory Properties Independent of NF-κB Through Conformational Constraint of Peptide-Based Interleukin-1 Receptor Biased Ligands, Frontiers in Chemistry, 7, 2019. Crossref

  4. Stefanucci Azzurra, Lei Wei, Pieretti Stefano, Novellino Ettore, Dimmito Marilisa Pia, Marzoli Francesca, Streicher John M., Mollica Adriano, On resin click-chemistry-mediated synthesis of novel enkephalin analogues with potent anti-nociceptive activity, Scientific Reports, 9, 1, 2019. Crossref

  5. Huang He, Damjanovic Jovan, Miao Jiayuan, Lin Yu-Shan, Cyclic peptides: backbone rigidification and capability of mimicking motifs at protein–protein interfaces, Physical Chemistry Chemical Physics, 23, 1, 2021. Crossref

  6. Jiang Yixiang, Liu Sha, Tian Gaofei, Cheung Hayden Jit Hei, Li Xin, Li Xiang David, Concise solid-phase synthesis enables derivatisation of YEATS domain cyclopeptide inhibitors for improved cellular uptake, Bioorganic & Medicinal Chemistry, 45, 2021. Crossref

  7. Sindhikara Dan, Wagner Michael, Gkeka Paraskevi, Güssregen Stefan, Tiwari Garima, Hessler Gerhard, Yapici Engin, Li Ziyu, Evers Andreas, Automated Design of Macrocycles for Therapeutic Applications: From Small Molecules to Peptides and Proteins, Journal of Medicinal Chemistry, 63, 20, 2020. Crossref

  8. Qvit Nir, Peptides and Peptidomimetics as Foundations for Drug Discovery, in Encyclopedia of Molecular Pharmacology, 2021. Crossref

  9. Rubin Samuel J.S., Qvit Nir, Engineering “Antimicrobial Peptides” and Other Peptides to Modulate Protein-Protein Interactions in Cancer, Current Topics in Medicinal Chemistry, 20, 32, 2020. Crossref

  10. Yip Chee-Hoo, Mahalingam Sobina, Wan Kiew-Lian, Nathan Sheila, Karunasagar Iddya, Prodigiosin inhibits bacterial growth and virulence factors as a potential physiological response to interspecies competition, PLOS ONE, 16, 6, 2021. Crossref

  11. Zhang Yue, Zhang Qing, Wong Clarence T. T., Li Xuechen, Chemoselective Peptide Cyclization and Bicyclization Directly on Unprotected Peptides, Journal of the American Chemical Society, 141, 31, 2019. Crossref

  12. Łepek Teresa, Kwiatkowska Anna, Couture Frédéric, Ly Kévin, Desjardins Roxane, Dory Yves, Prahl Adam, Day Robert, Macrocyclization of a potent PACE4 inhibitor: Benefits and limitations, European Journal of Cell Biology, 96, 5, 2017. Crossref

  13. Jiwacharoenchai Nattanan, Tabtimmai Lueacha, Kiriwan Duangnapa, Suwattanasophon Chonticha, Seetaha Supaphorn, Sinthuvanich Chomdao, Choowongkomon Kiattawee, A novel cyclic NP1 reveals obstruction of EGFR kinase activity and attenuation of EGFR‐driven cell lines, Journal of Cellular Biochemistry, 123, 2, 2022. Crossref

  14. Qvit Nir, Peptides and Peptidomimetics as Foundations for Drug Discovery, in Encyclopedia of Molecular Pharmacology, 2021. Crossref

  15. Choi Yoona, Lee Subin, Kim Heejun, Park Seung Bum, Design and Synthesis of Conformationally Diverse Pyrimidine-Embedded Medium/Macro- and Bridged Cycles via Skeletal Transformation, Frontiers in Chemistry, 10, 2022. Crossref

  16. Doller Dario, Allosteric Modulation, in Comprehensive Pharmacology, 2022. Crossref

  17. Ullrich Sven, George Josemon, Coram Alexandra E., Morewood Richard, Nitsche Christoph, Biocompatible and Selective Generation of Bicyclic Peptides**, Angewandte Chemie International Edition, 2022. Crossref

  18. Ullrich Sven, George Josemon, Coram Alexandra E., Morewood Richard, Nitsche Christoph, Biokompatible und selektive Generierung bizyklischer Peptide**, Angewandte Chemie, 2022. Crossref

  19. Dias Susana A, Pinto Sandra N, Silva-Herdade Ana S, Cheneval Olivier, Craik David J, Coutinho Ana, Castanho Miguel A R B, Henriques Sónia T, Veiga Ana Salomé, A designed cyclic analogue of gomesin has potent activity against Staphylococcus aureus biofilms, Journal of Antimicrobial Chemotherapy, 2022. Crossref

  20. Rubin Samuel J.S., Qvit Nir, Preface, in Peptide and Peptidomimetic Therapeutics, 2022. Crossref

  21. Rubin Samuel J.S., Qvit Nir, The current state of backbone cyclic peptidomimetics and their application to drug discovery, in Peptide and Peptidomimetic Therapeutics, 2022. Crossref

  22. Hanout Wessal, Qvit Nir, Antiparasitic therapeutic peptidomimetics, in Peptide and Peptidomimetic Therapeutics, 2022. Crossref

  23. Qvit Nir, Therapeutic peptides targeting protein kinase: progress, challenges, and future directions, featuring cancer and cardiovascular disease, in Peptide and Peptidomimetic Therapeutics, 2022. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain